Starling Oncology, Inc.
Starling Oncology, Inc., formerly The Oncology Institute, is a value-based oncology company advancing cancer care in the community setting. Founded in 2007, the company offers cutting-edge, evidence-based cancer treatments, including clinical trials and transfusions, to a large patient population. It operates as an…
1D
-6.9%
1W
-3.0%
1M
-1.5%
6M
–
YTD
–
1Y
–
2Y
–
5Y
–
10Y
–
Next earnings date
No date known
Volatility around earnings
~111% stronger price swings than usual
PRICE TARGET LOW
US$9.00
CONSENSUS
US$9.00
MEDIAN
US$9.00
PRICE TARGET HIGH
US$9.00
0
STRONG BUY
3
BUY
0
HOLD
0
SELL
0
STRONG SELL
3
TOTAL · Buy
As of: 14/10/2026
P/E
-21.43
P/B
-26.59
EV/EBITDA
-32.32
RETURN ON EQUITY
39.3%
NET MARGIN
-6.1%
DEBT/EQUITY
-4.19
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
FREE FLOAT
88.9%
FLOAT SHARES
88,888,178
AVG. DAILY VOLUME (30D)
1,315,428
Hively Brad
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -6.9%
Forums (Reddit)
Starling Oncology, Inc. is a company in the Healthcare sector, Medical - Care Facilities industry, headquartered in United States.
The CEO is Daniel Virnich, the company employs around 641 people.
The IPO was on 04/08/2026; the stock trades on NASDAQ under the ticker STLN.
3 analysts rate the stock, the consensus is Buy (as of 14/10/2026).
The average price target is US$9.00, ranging from US$9.00 to US$9.00, with a median of US$9.00.
This is an external assessment, not a statement by Market Jury.
Around past earnings, price swings were roughly 111% stronger than usual.
No, Starling Oncology currently does not pay a dividend.
Comparable stocks include HCA Healthcare, Tenet Healthcare, DaVita, Universal Health Services, Hims & Hers Health, LifeStance Health Group, Concentra Group Holdings Parent and Acadia Healthcare Company.
Clicking "Analyze stock" lets five strategies assess Starling Oncology against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.